Quantitative Systems Pharmacology Modeling of PBMC-Humanized Mouse to Facilitate Preclinical Immuno-oncology Drug Development

Progress in immunotherapy has resulted in explosively increased new therapeutic interventions and they have shown promising results in the treatment of cancer. Animal testing is performed to provide preliminary efficacy and safety data for drugs under development prior to clinical trials. However, t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:ACS pharmacology & translational science 2021-02, Vol.4 (1), p.213-225
Hauptverfasser: Ma, Huilin, Pilvankar, Minu, Wang, Jun, Giragossian, Craig, Popel, Aleksander S
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 225
container_issue 1
container_start_page 213
container_title ACS pharmacology & translational science
container_volume 4
creator Ma, Huilin
Pilvankar, Minu
Wang, Jun
Giragossian, Craig
Popel, Aleksander S
description Progress in immunotherapy has resulted in explosively increased new therapeutic interventions and they have shown promising results in the treatment of cancer. Animal testing is performed to provide preliminary efficacy and safety data for drugs under development prior to clinical trials. However, translational challenges remain for preclinical studies such as study design and the relevance of animal models to humans. Hence, only a small fraction of cancer patients showed response. The explosion of drug candidates and therapies makes preclinical assessment of every plausible option impossible, but it can be easily tested using Quantitative System Pharmacology (QSP) models. Here, we developed a QSP model for humanized mice. Tumor growth dynamics, T cell dynamics, cytokine release, immune checkpoint expression, and drug administration were modeled and calibrated using experimental data. Tumor growth inhibition data were used for model validation. Pharmacokinetics of T cell engager (TCE), tumor growth profile, T cell expansion in the blood and infiltration into tumor, T cell dissemination from primary tumor, cytokine release profile, and expression of additional PD-L1 induced by IFN-γ were modeled and calibrated using a variety of experimental data and showed good consistency. Mouse-specific response to T cell engager monotherapy also showed the key features of in vivo efficacy of TCE. This novel QSP model, designed for human peripheral blood mononuclear cells (PBMC) engrafted xenograft mice, incorporating the most critical components of the mouse model with key cancer and immune cells, can become an integral part of preclinical drug development.
doi_str_mv 10.1021/acsptsci.0c00178
format Article
fullrecord <record><control><sourceid>acs_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7887858</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>b273589904</sourcerecordid><originalsourceid>FETCH-LOGICAL-a433t-473d067c6ab54db01d2ef4b71b5a37d6cbfecaac6ac2ffec38f56f10896220003</originalsourceid><addsrcrecordid>eNp1kdFLwzAQxoMoTtR3nyR_gJ2Xpm26F0E3p4LiRH0O1zTdIm0zknYwwf_dyKbog093cN_3O-4-Qk4YDBnE7ByVX3ZemSEoACbyHXIQpyKNRgzy3V_9gBx7_wYAMQBnI9gnA84zljKRHJCPpx7bznTYmZWmz2vf6cbT2QJdg8rWdr6mD7bUtWnn1FZ0dvUwjm77Blvzrssw6r2mnaVTVKb-omg6c1oFuVFY07um6Vsb2XaLmrh-Tid6pWu7bHTbHZG9Cmuvj7f1kLxOr1_Gt9H9483d-PI-woTzLkoELyETKsMiTcoCWBnrKikEK1LkosxUUWmFGOYqrkLL8yrNqnD6KIvD0cAPycWGu-yLRpcqrHZYy6UzDbq1tGjk30lrFnJuV1LkucjTPABgA1DOeu909eNlIL_SkN9pyG0awXL6e-eP4fv3QXC2EQSrfLO9a8ML_ud9ApRTm14</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Quantitative Systems Pharmacology Modeling of PBMC-Humanized Mouse to Facilitate Preclinical Immuno-oncology Drug Development</title><source>PubMed Central</source><source>American Chemical Society Journals</source><creator>Ma, Huilin ; Pilvankar, Minu ; Wang, Jun ; Giragossian, Craig ; Popel, Aleksander S</creator><creatorcontrib>Ma, Huilin ; Pilvankar, Minu ; Wang, Jun ; Giragossian, Craig ; Popel, Aleksander S</creatorcontrib><description>Progress in immunotherapy has resulted in explosively increased new therapeutic interventions and they have shown promising results in the treatment of cancer. Animal testing is performed to provide preliminary efficacy and safety data for drugs under development prior to clinical trials. However, translational challenges remain for preclinical studies such as study design and the relevance of animal models to humans. Hence, only a small fraction of cancer patients showed response. The explosion of drug candidates and therapies makes preclinical assessment of every plausible option impossible, but it can be easily tested using Quantitative System Pharmacology (QSP) models. Here, we developed a QSP model for humanized mice. Tumor growth dynamics, T cell dynamics, cytokine release, immune checkpoint expression, and drug administration were modeled and calibrated using experimental data. Tumor growth inhibition data were used for model validation. Pharmacokinetics of T cell engager (TCE), tumor growth profile, T cell expansion in the blood and infiltration into tumor, T cell dissemination from primary tumor, cytokine release profile, and expression of additional PD-L1 induced by IFN-γ were modeled and calibrated using a variety of experimental data and showed good consistency. Mouse-specific response to T cell engager monotherapy also showed the key features of in vivo efficacy of TCE. This novel QSP model, designed for human peripheral blood mononuclear cells (PBMC) engrafted xenograft mice, incorporating the most critical components of the mouse model with key cancer and immune cells, can become an integral part of preclinical drug development.</description><identifier>ISSN: 2575-9108</identifier><identifier>EISSN: 2575-9108</identifier><identifier>DOI: 10.1021/acsptsci.0c00178</identifier><identifier>PMID: 33615174</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><ispartof>ACS pharmacology &amp; translational science, 2021-02, Vol.4 (1), p.213-225</ispartof><rights>2020 American Chemical Society</rights><rights>2020 American Chemical Society.</rights><rights>2020 American Chemical Society 2020 American Chemical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a433t-473d067c6ab54db01d2ef4b71b5a37d6cbfecaac6ac2ffec38f56f10896220003</citedby><cites>FETCH-LOGICAL-a433t-473d067c6ab54db01d2ef4b71b5a37d6cbfecaac6ac2ffec38f56f10896220003</cites><orcidid>0000-0003-4238-9475</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acsptsci.0c00178$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acsptsci.0c00178$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,2765,27076,27924,27925,53791,53793,56738,56788</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33615174$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ma, Huilin</creatorcontrib><creatorcontrib>Pilvankar, Minu</creatorcontrib><creatorcontrib>Wang, Jun</creatorcontrib><creatorcontrib>Giragossian, Craig</creatorcontrib><creatorcontrib>Popel, Aleksander S</creatorcontrib><title>Quantitative Systems Pharmacology Modeling of PBMC-Humanized Mouse to Facilitate Preclinical Immuno-oncology Drug Development</title><title>ACS pharmacology &amp; translational science</title><addtitle>ACS Pharmacol. Transl. Sci</addtitle><description>Progress in immunotherapy has resulted in explosively increased new therapeutic interventions and they have shown promising results in the treatment of cancer. Animal testing is performed to provide preliminary efficacy and safety data for drugs under development prior to clinical trials. However, translational challenges remain for preclinical studies such as study design and the relevance of animal models to humans. Hence, only a small fraction of cancer patients showed response. The explosion of drug candidates and therapies makes preclinical assessment of every plausible option impossible, but it can be easily tested using Quantitative System Pharmacology (QSP) models. Here, we developed a QSP model for humanized mice. Tumor growth dynamics, T cell dynamics, cytokine release, immune checkpoint expression, and drug administration were modeled and calibrated using experimental data. Tumor growth inhibition data were used for model validation. Pharmacokinetics of T cell engager (TCE), tumor growth profile, T cell expansion in the blood and infiltration into tumor, T cell dissemination from primary tumor, cytokine release profile, and expression of additional PD-L1 induced by IFN-γ were modeled and calibrated using a variety of experimental data and showed good consistency. Mouse-specific response to T cell engager monotherapy also showed the key features of in vivo efficacy of TCE. This novel QSP model, designed for human peripheral blood mononuclear cells (PBMC) engrafted xenograft mice, incorporating the most critical components of the mouse model with key cancer and immune cells, can become an integral part of preclinical drug development.</description><issn>2575-9108</issn><issn>2575-9108</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kdFLwzAQxoMoTtR3nyR_gJ2Xpm26F0E3p4LiRH0O1zTdIm0zknYwwf_dyKbog093cN_3O-4-Qk4YDBnE7ByVX3ZemSEoACbyHXIQpyKNRgzy3V_9gBx7_wYAMQBnI9gnA84zljKRHJCPpx7bznTYmZWmz2vf6cbT2QJdg8rWdr6mD7bUtWnn1FZ0dvUwjm77Blvzrssw6r2mnaVTVKb-omg6c1oFuVFY07um6Vsb2XaLmrh-Tid6pWu7bHTbHZG9Cmuvj7f1kLxOr1_Gt9H9483d-PI-woTzLkoELyETKsMiTcoCWBnrKikEK1LkosxUUWmFGOYqrkLL8yrNqnD6KIvD0cAPycWGu-yLRpcqrHZYy6UzDbq1tGjk30lrFnJuV1LkucjTPABgA1DOeu909eNlIL_SkN9pyG0awXL6e-eP4fv3QXC2EQSrfLO9a8ML_ud9ApRTm14</recordid><startdate>20210212</startdate><enddate>20210212</enddate><creator>Ma, Huilin</creator><creator>Pilvankar, Minu</creator><creator>Wang, Jun</creator><creator>Giragossian, Craig</creator><creator>Popel, Aleksander S</creator><general>American Chemical Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4238-9475</orcidid></search><sort><creationdate>20210212</creationdate><title>Quantitative Systems Pharmacology Modeling of PBMC-Humanized Mouse to Facilitate Preclinical Immuno-oncology Drug Development</title><author>Ma, Huilin ; Pilvankar, Minu ; Wang, Jun ; Giragossian, Craig ; Popel, Aleksander S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a433t-473d067c6ab54db01d2ef4b71b5a37d6cbfecaac6ac2ffec38f56f10896220003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ma, Huilin</creatorcontrib><creatorcontrib>Pilvankar, Minu</creatorcontrib><creatorcontrib>Wang, Jun</creatorcontrib><creatorcontrib>Giragossian, Craig</creatorcontrib><creatorcontrib>Popel, Aleksander S</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>ACS pharmacology &amp; translational science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ma, Huilin</au><au>Pilvankar, Minu</au><au>Wang, Jun</au><au>Giragossian, Craig</au><au>Popel, Aleksander S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quantitative Systems Pharmacology Modeling of PBMC-Humanized Mouse to Facilitate Preclinical Immuno-oncology Drug Development</atitle><jtitle>ACS pharmacology &amp; translational science</jtitle><addtitle>ACS Pharmacol. Transl. Sci</addtitle><date>2021-02-12</date><risdate>2021</risdate><volume>4</volume><issue>1</issue><spage>213</spage><epage>225</epage><pages>213-225</pages><issn>2575-9108</issn><eissn>2575-9108</eissn><abstract>Progress in immunotherapy has resulted in explosively increased new therapeutic interventions and they have shown promising results in the treatment of cancer. Animal testing is performed to provide preliminary efficacy and safety data for drugs under development prior to clinical trials. However, translational challenges remain for preclinical studies such as study design and the relevance of animal models to humans. Hence, only a small fraction of cancer patients showed response. The explosion of drug candidates and therapies makes preclinical assessment of every plausible option impossible, but it can be easily tested using Quantitative System Pharmacology (QSP) models. Here, we developed a QSP model for humanized mice. Tumor growth dynamics, T cell dynamics, cytokine release, immune checkpoint expression, and drug administration were modeled and calibrated using experimental data. Tumor growth inhibition data were used for model validation. Pharmacokinetics of T cell engager (TCE), tumor growth profile, T cell expansion in the blood and infiltration into tumor, T cell dissemination from primary tumor, cytokine release profile, and expression of additional PD-L1 induced by IFN-γ were modeled and calibrated using a variety of experimental data and showed good consistency. Mouse-specific response to T cell engager monotherapy also showed the key features of in vivo efficacy of TCE. This novel QSP model, designed for human peripheral blood mononuclear cells (PBMC) engrafted xenograft mice, incorporating the most critical components of the mouse model with key cancer and immune cells, can become an integral part of preclinical drug development.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>33615174</pmid><doi>10.1021/acsptsci.0c00178</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0003-4238-9475</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2575-9108
ispartof ACS pharmacology & translational science, 2021-02, Vol.4 (1), p.213-225
issn 2575-9108
2575-9108
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7887858
source PubMed Central; American Chemical Society Journals
title Quantitative Systems Pharmacology Modeling of PBMC-Humanized Mouse to Facilitate Preclinical Immuno-oncology Drug Development
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T01%3A27%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-acs_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quantitative%20Systems%20Pharmacology%20Modeling%20of%20PBMC-Humanized%20Mouse%20to%20Facilitate%20Preclinical%20Immuno-oncology%20Drug%20Development&rft.jtitle=ACS%20pharmacology%20&%20translational%20science&rft.au=Ma,%20Huilin&rft.date=2021-02-12&rft.volume=4&rft.issue=1&rft.spage=213&rft.epage=225&rft.pages=213-225&rft.issn=2575-9108&rft.eissn=2575-9108&rft_id=info:doi/10.1021/acsptsci.0c00178&rft_dat=%3Cacs_pubme%3Eb273589904%3C/acs_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33615174&rfr_iscdi=true